GlaxoSmithKline plc (GSK) acquired, on a worldwide basis, the injectable anti-thrombotic agents Fraxiparine, Fraxodi and Arixtra and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Aventis. As part of this transaction, GSK assumes responsibility for ongoing Arixtra clinical trials.
The closing of this divestiture transaction follows Sanofi-Synthelabo's successful completion of its offer for Aventis, after obtaining the requisite clearances from EU and US competition authorities.
Fraxiparine (nadroparine calcium) is a Low Molecular Weight Heparin and Arixtra (fondaparinux sodium) is a selective factor Xa inhibitor. Sales of Fraxiparine were EUR 319 million in 2003. Worldwide sales of Arixtra were EUR 24 million in 2003.
The manufacturing facility located in Notre-Dame de Bondeville, France is engaged mainly in the manufacture of Fraxiparine and Arixtra injectable products. This facility employs approximately 650 people.
Pharmaceuticals Europe president, Andrew Witty said: "We are very pleased with this acquisition. These are great products which will provide GSK with good commercial opportunities and help strengthen our portfolio in the hospital business."